1898P A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001

We report the results of a single-arm, prospective, non-randomized, non-comparative, open label, multicenter, phase II trial designed to assess the activity and safety of cisplatin, pemetrexed, and nivolumab as first line therapy in MPM. This trial has been registered as UMIN000030892. Enrollment criteria were as follows: patients older than 20 years with pathologically confirmed, untreated, unresectable MPM, with measurable lesions and an...